Edition:
United States

Intellia Therapeutics Inc (NTLA.OQ)

NTLA.OQ on NASDAQ Stock Exchange Global Market

19.14USD
11 Dec 2017
Change (% chg)

$-2.08 (-9.80%)
Prev Close
$21.22
Open
$21.79
Day's High
$22.02
Day's Low
$18.34
Volume
403,365
Avg. Vol
194,906
52-wk High
$33.20
52-wk Low
$10.83

Latest Key Developments (Source: Significant Developments)

Intellia Therapeutics prices public offering of 6.3 mln shares at $24 per share
Wednesday, 1 Nov 2017 09:00pm EDT 

Nov 1 (Reuters) - Intellia Therapeutics Inc :Intellia Therapeutics announces pricing of public offering of common stock.Says ‍priced public offering of 6.3 million shares of its common stock at a public offering price of $24.00 per share​.  Full Article

Intellia Therapeutics announces proposed public offering of common stock
Wednesday, 1 Nov 2017 07:00am EDT 

Nov 1 (Reuters) - Intellia Therapeutics Inc NTLA.O:Intellia therapeutics announces proposed public offering of common stock.Intellia therapeutics inc - ‍has commenced an underwritten public offering of $150 million of its common stock​.  Full Article

Intellia Therapeutics Q3 revenue $65 mln
Tuesday, 31 Oct 2017 07:30am EDT 

Oct 31 (Reuters) - Intellia Therapeutics Inc -:Intellia Therapeutics announces third quarter 2017 financial results.Q3 revenue $65 million.Q3 revenue view $5.9 million -- Thomson Reuters I/B/E/S.Says ‍well-tolerated safety profile observed for CRISPR/CAS9.  Full Article

Intellia Therapeutics Q3 loss per share $‍0.44​
Tuesday, 31 Oct 2017 07:30am EDT 

Oct 31 (Reuters) - Intellia Therapeutics Inc ::Intellia therapeutics announces third quarter 2017 financial results.Q3 collaboration revenue $7.3 million versus $4.9 million.Q3 revenue view $5.9 million -- Thomson Reuters I/B/E/S.Says ‍well-tolerated safety profile observed for CRISPR/Cas9.Qtrly loss per share $‍0.44​.Q3 earnings per share view $-0.50 -- Thomson Reuters I/B/E/S.  Full Article

Intellia Therapeutics reports Q2 revenue $69.6 million
Tuesday, 1 Aug 2017 07:30am EDT 

Aug 1 (Reuters) - Intellia Therapeutics Inc :Intellia Therapeutics announces second quarter 2017 financial results.Q2 revenue $69.6 million.Q2 revenue view $5.8 million -- Thomson Reuters I/B/E/S.Intellia Therapeutics Inc qtrly loss per share $0.45.Q2 earnings per share view $-0.42 -- Thomson Reuters I/B/E/S.Intellia Therapeutics - expect that cash, cash equivalents as of June 30 will enable co to fund operating expenses, capital expenditures through mid-2019.  Full Article

Intellia Therapeutics and San Raffaele University and Research Hospital to combine CRISPR/cas9 genome editing with enhanced cell therapies
Tuesday, 6 Jun 2017 07:15am EDT 

June 6 (Reuters) - Intellia Therapeutics Inc :Intellia Therapeutics and San Raffaele University And Research Hospital to combine CRISPR/cas9 genome editing with enhanced cell therapies to fight cancer.  Full Article

Intellia Therapeutics reports qtrly loss per share of $0.36
Tuesday, 2 May 2017 07:30am EDT 

May 2 (Reuters) - Intellia Therapeutics Inc : :Intellia Therapeutics announces first quarter 2017 financial results.Q1 collaboration revenue $6.2 million.Qtrly loss per share $0.36.Cash and cash equivalents at march 31, 2017, were $258 million, compared to $64 million for same quarter in 2016.During 2017, co expects expenses to continue to increase compared to prior periods.  Full Article

Intellia therapeutics announces European Patent Office's decision
Tuesday, 11 Apr 2017 07:30am EDT 

Intellia Therapeutics Inc : Intellia Therapeutics announces European Patent Office's decision to grant crispr/cas9 genome editing technology patent . Intellia Therapeutics - patent covers compositions of crispr single guide RNA technology for use in non-cellular, cellular settings, including eukaryotic cells . Intellia Therapeutics - EPO's decision to grant patent follows its March 24, notice of intent to issue patent, which was not challenged by any third party .Intellia Therapeutics - European patent will cover, approximately forty European countries, including Germany, Italy, France, Spain and Netherlands.  Full Article

Intellia Therapeutics qtrly loss per share $0.31
Tuesday, 14 Mar 2017 07:15am EDT 

Intellia Therapeutics Inc : Intellia therapeutics announces fourth quarter and full-year 2016 financial results . Intellia therapeutics inc - cash and cash equivalents at december 31, 2016, were $273.1 million, compared to $75.8 million at december 31, 2015 . Intellia therapeutics inc - qtrly loss per share $0.31 . Intellia therapeutics inc- during 2017, expects expenses to increase compared to prior periods . Intellia therapeutics inc - collaboration revenue was $5.6 million for q4 of 2016, as compared to $1.7 million for q4 of 2015 .Intellia therapeutics- expect cash,cash equivalents as of dec 31, 2016 will enable co to fund operating expenses,capital expenditures through mid-2019.  Full Article

Intellia Therapeutics qtrly net loss of $6.9 mln vs net loss of $3 mln in Q2 2015
Thursday, 4 Aug 2016 04:10pm EDT 

Intellia Therapeutics Inc : Intellia therapeutics reports financial results for second quarter 2016 . Collaboration revenue was $4.2 million in q2 2016, compared to $1.4 million in same period of 2015 .Qtrly net loss of $6.9 million versus net loss of $3 million in q2 2015.  Full Article